Honor Jason's legacy by ensuring tomorrow's young leaders can access real-world opportunities through NYLI. Driven and vibrant, Jason pursued a rich, meaningful life, despite complications from his hemophilia diagnosis and treatment. Jason's memory…
Named in honor of Dr. Judith Graham Pool, NBDF's premier research fellowship program provides support for basic science and pre-clinical bleeding disorders research. JGP Fellows, whose work is made possible by generous donors like you, improve care…
Adam Lynch was a loyal friend, an original thinker, and a clever writer whose life was cut short by a bleeding disorder. Created to celebrate Adam's drive, this scholarship awards like-minded young community members (affected directly or indirectly…
Your gift, no matter the size, provides critical support to the inheritable blood disorders community. From researching better treatment options, to advocating for quality healthcare, to creating tailored educational events, NBDF’s work for this…
Objective:
Immune tolerance induction (ITI) is the standard of care for inhibitor eradication and restoration of factor VIII (FVIII) responsiveness in subjects with severe hemophilia who develop high-titer inhibitors.…
.flip-card {
background-color: transparent;
min-width: 100%;
height:500px;
perspective: 1000px;
}
.flip-card-inner {
position: relative;
width: 100%;
height: 100%;
text-align: center;
transition: transform 0.6s;…
Spark Therapeutics recently announced updates from an ongoing phase 1/2 clinical trial of SPK-8011, the company’s investigational gene therapy candidate for hemophilia A. Administered via a one-time intravenous infusion, SPK-8011 is designed to…
FOR IMMEDIATE RELEASE
Media Contact
Ilana Ostrin
iostrin@hemophilia.org
212-328-3769
NHF Announces New Partnership with InSourceRx
A portion of proceeds from InSourceRx will benefit NHF
New York, NY - InSourceRx, a Nebraska-based…